Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Borderline Product Court Ruling Puts Tricky “Negative Burden Of Proof” On Manufacturers

Executive Summary

When is a borderline drug/device product a medical device? Only when the manufacturer can prove that is definitely not a medicine, according to a new EU Court Of Justice ruling. Expert medtech regulatory lawyer Erik Vollebregt outlines his main criticisms of this judgment.

You may also be interested in...



Device/Drug Borderline: Gray Areas Remain Despite New EU Guidance

The regulation of products on the drug/device borderline has always been complex. New EU guidance aims to provide clarification, but some difficult and nuanced decision-making is still left to the manufacturer.

Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease

Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.

How Innovative UTI Diagnostics Can Help Combat Antibiotic Resistance

UTIs are one of the most common reasons for antibiotics to be prescribed, but accurate and timely diagnostic tools are lacking. England’s NICE has identified four innovative IVDs that could be rolled out for NHS patients, but said more research is needed on these products first.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel